Clotam enhances anti-proliferative effect of vincristine in Ewing sarcoma cells

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Current therapeutic strategies used in Ewing sarcoma (ES) especially for relapsed patients have resulted in modest improvements in survival over the past 20 years. Combination therapeutic approach presents as an alternative to overcoming drug resistance in metastatic ES. This study evaluated the effect of Clotam (tolfenamic acid or TA), a small molecule and inhibitor of Specificity protein1 (Sp1) and survivin for sensitizing ES cell lines to chemotherapeutic agent, vincristine (VCR). ES cells (CHLA-9 and TC-32) were treated with TA or VCR or TA + VCR (combination), and cell viability was assessed after 24/48/72 h. Effect of TA or VCR or TA + VCR treatment on cell cycle arrest and apoptosis were evaluated using propidium iodide, cell cycle assay and Annexin V flow cytometry respectively. The apoptosis markers, caspase 3/7 (activity levels) and cleaved-PARP (protein expression) were measured. Cardiomyocytes, H9C2 were used as non-malignant cells. While, all treatments caused time- and dose-dependent inhibition of cell viability, interestingly, combination treatment caused significantly higher response (~ 80% inhibition, p < 0.05). Cell viability inhibition was accompanied by inhibition of Sp1 and Survivin. TA + VCR treatment significantly (p < 0.05) increased caspase 3/7 activity which strongly correlated with upregulated c-PARP level and Annexin V staining. Cell cycle arrest was observed at G0/G1 (TA) or G2/M (VCR and TA + VCR). All treatments did not cause cytotoxicity in H9C2 cells. These results suggest that TA could enhance the anti-cancer activity of VCR in ES cells. Therefore, TA + VCR combination could be further tested to develop as safe/effective therapeutic strategy for treating ES.

Original languageEnglish
Pages (from-to)21-32
Number of pages12
JournalApoptosis
Volume24
Issue number1-2
DOIs
StatePublished - 15 Feb 2019

Fingerprint

Ewing's Sarcoma
Vincristine
Cells
Caspase 7
Cell Survival
Annexin A5
Therapeutics
Cell Cycle Checkpoints
Caspase 3
Apoptosis
tolfenamic acid
Flow cytometry
Propidium
Cytotoxicity
Drug Resistance
Cardiac Myocytes
Assays
Cell Cycle
Flow Cytometry
Staining and Labeling

Keywords

  • Ewing sarcoma
  • Sp1
  • Survivin
  • Tolfenamic acid
  • Vincristine

Cite this

@article{b7c5314ee1ce4319b4717fc5e7d24e5a,
title = "Clotam enhances anti-proliferative effect of vincristine in Ewing sarcoma cells",
abstract = "Current therapeutic strategies used in Ewing sarcoma (ES) especially for relapsed patients have resulted in modest improvements in survival over the past 20 years. Combination therapeutic approach presents as an alternative to overcoming drug resistance in metastatic ES. This study evaluated the effect of Clotam (tolfenamic acid or TA), a small molecule and inhibitor of Specificity protein1 (Sp1) and survivin for sensitizing ES cell lines to chemotherapeutic agent, vincristine (VCR). ES cells (CHLA-9 and TC-32) were treated with TA or VCR or TA + VCR (combination), and cell viability was assessed after 24/48/72 h. Effect of TA or VCR or TA + VCR treatment on cell cycle arrest and apoptosis were evaluated using propidium iodide, cell cycle assay and Annexin V flow cytometry respectively. The apoptosis markers, caspase 3/7 (activity levels) and cleaved-PARP (protein expression) were measured. Cardiomyocytes, H9C2 were used as non-malignant cells. While, all treatments caused time- and dose-dependent inhibition of cell viability, interestingly, combination treatment caused significantly higher response (~ 80{\%} inhibition, p < 0.05). Cell viability inhibition was accompanied by inhibition of Sp1 and Survivin. TA + VCR treatment significantly (p < 0.05) increased caspase 3/7 activity which strongly correlated with upregulated c-PARP level and Annexin V staining. Cell cycle arrest was observed at G0/G1 (TA) or G2/M (VCR and TA + VCR). All treatments did not cause cytotoxicity in H9C2 cells. These results suggest that TA could enhance the anti-cancer activity of VCR in ES cells. Therefore, TA + VCR combination could be further tested to develop as safe/effective therapeutic strategy for treating ES.",
keywords = "Ewing sarcoma, Sp1, Survivin, Tolfenamic acid, Vincristine",
author = "Sagar Shelake and Sankpal, {Umesh Tanaji} and Don Eslin and Paul Bowman and Jerry Simecka and Raut, {Sangram Limbaji} and Anish Ray and Basha, {Riyaz Mahammad}",
year = "2019",
month = "2",
day = "15",
doi = "10.1007/s10495-018-1508-1",
language = "English",
volume = "24",
pages = "21--32",
journal = "Apoptosis",
issn = "1360-8185",
publisher = "Springer Netherlands",
number = "1-2",

}

Clotam enhances anti-proliferative effect of vincristine in Ewing sarcoma cells. / Shelake, Sagar; Sankpal, Umesh Tanaji; Eslin, Don; Bowman, Paul; Simecka, Jerry; Raut, Sangram Limbaji; Ray, Anish; Basha, Riyaz Mahammad.

In: Apoptosis, Vol. 24, No. 1-2, 15.02.2019, p. 21-32.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Clotam enhances anti-proliferative effect of vincristine in Ewing sarcoma cells

AU - Shelake, Sagar

AU - Sankpal, Umesh Tanaji

AU - Eslin, Don

AU - Bowman, Paul

AU - Simecka, Jerry

AU - Raut, Sangram Limbaji

AU - Ray, Anish

AU - Basha, Riyaz Mahammad

PY - 2019/2/15

Y1 - 2019/2/15

N2 - Current therapeutic strategies used in Ewing sarcoma (ES) especially for relapsed patients have resulted in modest improvements in survival over the past 20 years. Combination therapeutic approach presents as an alternative to overcoming drug resistance in metastatic ES. This study evaluated the effect of Clotam (tolfenamic acid or TA), a small molecule and inhibitor of Specificity protein1 (Sp1) and survivin for sensitizing ES cell lines to chemotherapeutic agent, vincristine (VCR). ES cells (CHLA-9 and TC-32) were treated with TA or VCR or TA + VCR (combination), and cell viability was assessed after 24/48/72 h. Effect of TA or VCR or TA + VCR treatment on cell cycle arrest and apoptosis were evaluated using propidium iodide, cell cycle assay and Annexin V flow cytometry respectively. The apoptosis markers, caspase 3/7 (activity levels) and cleaved-PARP (protein expression) were measured. Cardiomyocytes, H9C2 were used as non-malignant cells. While, all treatments caused time- and dose-dependent inhibition of cell viability, interestingly, combination treatment caused significantly higher response (~ 80% inhibition, p < 0.05). Cell viability inhibition was accompanied by inhibition of Sp1 and Survivin. TA + VCR treatment significantly (p < 0.05) increased caspase 3/7 activity which strongly correlated with upregulated c-PARP level and Annexin V staining. Cell cycle arrest was observed at G0/G1 (TA) or G2/M (VCR and TA + VCR). All treatments did not cause cytotoxicity in H9C2 cells. These results suggest that TA could enhance the anti-cancer activity of VCR in ES cells. Therefore, TA + VCR combination could be further tested to develop as safe/effective therapeutic strategy for treating ES.

AB - Current therapeutic strategies used in Ewing sarcoma (ES) especially for relapsed patients have resulted in modest improvements in survival over the past 20 years. Combination therapeutic approach presents as an alternative to overcoming drug resistance in metastatic ES. This study evaluated the effect of Clotam (tolfenamic acid or TA), a small molecule and inhibitor of Specificity protein1 (Sp1) and survivin for sensitizing ES cell lines to chemotherapeutic agent, vincristine (VCR). ES cells (CHLA-9 and TC-32) were treated with TA or VCR or TA + VCR (combination), and cell viability was assessed after 24/48/72 h. Effect of TA or VCR or TA + VCR treatment on cell cycle arrest and apoptosis were evaluated using propidium iodide, cell cycle assay and Annexin V flow cytometry respectively. The apoptosis markers, caspase 3/7 (activity levels) and cleaved-PARP (protein expression) were measured. Cardiomyocytes, H9C2 were used as non-malignant cells. While, all treatments caused time- and dose-dependent inhibition of cell viability, interestingly, combination treatment caused significantly higher response (~ 80% inhibition, p < 0.05). Cell viability inhibition was accompanied by inhibition of Sp1 and Survivin. TA + VCR treatment significantly (p < 0.05) increased caspase 3/7 activity which strongly correlated with upregulated c-PARP level and Annexin V staining. Cell cycle arrest was observed at G0/G1 (TA) or G2/M (VCR and TA + VCR). All treatments did not cause cytotoxicity in H9C2 cells. These results suggest that TA could enhance the anti-cancer activity of VCR in ES cells. Therefore, TA + VCR combination could be further tested to develop as safe/effective therapeutic strategy for treating ES.

KW - Ewing sarcoma

KW - Sp1

KW - Survivin

KW - Tolfenamic acid

KW - Vincristine

UR - http://www.scopus.com/inward/record.url?scp=85059507311&partnerID=8YFLogxK

U2 - 10.1007/s10495-018-1508-1

DO - 10.1007/s10495-018-1508-1

M3 - Article

VL - 24

SP - 21

EP - 32

JO - Apoptosis

JF - Apoptosis

SN - 1360-8185

IS - 1-2

ER -